Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C
- 1.4k Downloads
A once-daily, single-tablet, pangenotypic regimen comprising the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir and the HCV NS5A inhibitor velpatasvir (sofosbuvir/velpatasvir; Epclusa®) was recently approved for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in the USA, EU and Canada. In the phase III ASTRAL trials, once-daily oral sofosbuvir/velpatasvir for 12 weeks provided very high rates of sustained virological response at 12 weeks post treatment (SVR12) in treatment-naive and -experienced patients with chronic HCV genotype 1–6 infection, including those with compensated cirrhosis or HIV-1 co-infection. High SVR12 rates were also observed with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with chronic HCV genotype 1–6 infection and decompensated cirrhosis. Sofosbuvir/velpatasvir was generally well tolerated, with low rates of adverse events. Thus, sofosbuvir/velpatasvir represents a valuable treatment option in adults with chronic HCV genotype 1–6 infection, including those with compensated or decompensated cirrhosis, previous treatment experience or HIV-1 co-infection.
KeywordsSustained Virological Response Sofosbuvir Decompensated Cirrhosis SVR12 Rate NS5A RAVs
During the peer review process, the manufacturer of sofosbuvir/velpatasvir was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Sarah Greig is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 2.American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2016. http://www.hcvguidelines.org. Accessed 23 Sep 2016.
- 5.Zhang J, Nguyen D, Hu KQ. Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies. N Am J Med Sci. 2016;9(2):47–54.Google Scholar
- 6.Gilead Sciences Inc. Epclusa® (sofosbuvir and velpatasvir) tablets, for oral use: US prescribing information. 2016. http://www.fda.gov. Accessed 23 Sep 2016.
- 7.Gilead Sciences International Ltd. Epclusa® 400/100 mg film-coated tablets: EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 23 Sep 2016.
- 8.Gilead Sciences Canada. Epclusa™ (sofosbuvir/velpatasvir) tablets 400 mg/100 mg antiviral agent: Canadian product monograph. 2016. http://www.gilead.ca. Accessed 23 Sep 2016.
- 15.Bräu N, Wyles D, Kottilil S, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study [abstract no. WEAB0301 plus slides]. In: International AIDS Conference. 2016.Google Scholar
- 16.Hezode C, Reau N, Svarovskaia E, et al. Resistance analysis in 1284 patients with genotype 1 to 6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4 studies [abstract no. THU-216 plus poster]. J Hepatol. 2016;64(Suppl 2):S399–400.CrossRefGoogle Scholar
- 18.Mogalian E, Brainard D, Denning J, et al. Evaluation of the effect of GS-5816, a pangenotypic HCV NS5A inhibitor, on the QT/QTc interval in healthy subjects [abstract no. 45 plus poster]. Rev Antivir Ther Infect Dis. 2015;4:49–50.Google Scholar
- 19.Mogalian E, Osinusi A, Shen G, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of sofosbuvir/velpatasvir fixed-dose combination tablet [abstract no. PI-050 plus poster]. Clin Pharmacol Ther. 2016;99(Suppl 1):S43–4.Google Scholar
- 21.Mogalian E, Brainard D, McNally J, et al. Lack of clinically relevant pharmacokinetic drug-drug interaction between norgestimate/ethinyl estradiol and pangenotypic HCV NS5A inhibitor GS-5816 in HCV-uninfected female subjects [abstract no. 1998 plus poster]. Hepatology. 2014;60(4 Suppl):1173A.Google Scholar
- 22.Mogalian E, McNally J, Shen G, et al. Drug-drug interaction profile of sofosbuvir/velpatasvir fixed-dose combination [abstract no. FRI-168]. J Hepatol. 2016;64(2 Suppl 1):S613–4.Google Scholar
- 23.Mogalian E, Naik S, Natha M, et al. Drug-drug interaction studies between HCV antivirals sofosbuvir and velpatasvir and HIV antiretrovirals [abstract no. P6]. HIV Med. 2016;17(Suppl 1):16.Google Scholar
- 24.Mogalian E, Stamm LM, Osinusi A, et al. Drug interaction studies between sofosbuvir/velpatasvir and boosted HIV ARV regimens [abstract no. 100 plus slides]. In: Conference on Retroviruses and Opportunistic Infections. 2016.Google Scholar
- 27.Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5 acontaining DAA regimens: results of the GS-US-342-1553 study [abstract no. PS024 plus slides]. J Hepatol. 2016;64(2 Suppl 1):S147–8.Google Scholar
- 28.Asselah T, Shafran S, Bourgeois S, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in HCV infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 study) [abstract no. SAT-279 plus poster]. J Hepatol. 2016;64(Suppl 2):S827–8.Google Scholar
- 29.Alqatani S, Zeuzem S, Bourgeois S, et al. On treatment HCV RNA as a predictor of SVR12 in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir fixed dose combination for 12 weeks: an analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies [abstract no. SAT-257 plus poster]. J Hepatol. 2016;64(Suppl 2):S817.CrossRefGoogle Scholar
- 30.Agarwal K, Patel K, Samuel D, et al. SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2 and ASTRAL-3 studies [abstract no. SAT-195 plus poster]. J Hepatol. 2016;64(Suppl 2):S787–8.CrossRefGoogle Scholar
- 31.O’Leary J, Brown RS, Reddy KR, et al. Baseline clinical and laboratory parameters associated with clinical benefits of successful HCV treatment with sofosbuvir/velpatasvir in decompensated cirrhotic patients [abstract no. SAT-169 plus slides]. J Hepatol. 2016;64(2 Suppl 1):S774.Google Scholar
- 32.Younossi ZM, Stepanova M, Charlton M, et al. Efficacy and patient-reported outcomes in decompensated cirrhotic with chronic hepatitis C treated with sofosbuvir and velpatasvir with or without ribavirin: results from ASTRAL-4 clinical trial [abstract no. SAT-285 plus poster]. J Hepatol. 2016;64(Suppl 2):S830.Google Scholar
- 33.Younossi ZM, Stepanova M, Feld J, et al. Impressive gains in patient-reported outcomes are observed in chronic hepatitis C patients with or without cirrhosis who are treated with sofosbuvir and velpatasvir: results from ASTRAL-1, -2, -3 and-4 [abstract no. FRI-200 plus poster]. J Hepatol. 2016;64(Suppl 2):S628.CrossRefGoogle Scholar
- 36.Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from ASTRAL-2 and -3 clinical trials. Clin Infect Dis. 2016. doi: 10.1093/cid/ciw496.PubMedGoogle Scholar